Erlina 10mg/5mg Tablets (30s)

Description

Erlina is a prescription combination medicine containing empagliflozin and linagliptin. It is used with diet and exercise to improve blood-glucose control in adults with type 2 diabetes.

• Drug Class: SGLT2 inhibitor and DPP-4 inhibitor antidiabetic combination
• Dosage Form: Tablet
• Storage: Store at room temperature in a dry place, protected from direct light, heat, and moisture. Keep out of reach of children.
• Pack Size: Pack of 30

Erlina 10mg/5mg Tablets (30s) Available Online in Pakistan

Dwatson offers Erlina 10mg/5mg Tablets (30s) at Rs.1517.7, with fast, discreet delivery across Pakistan.

Ingredients

• Empagliflozin 10 mg
• Linagliptin 5 mg

Benefits

• Improves blood-glucose control in adults with type 2 diabetes mellitus.
• Used together with diet and exercise.
• May be used alone or with other glucose-lowering medicines when prescribed by a healthcare professional.

Usage & Safety

For Adult

• Usual dose: one tablet once daily, taken at approximately the same time each day.
• May be taken with or without food and swallowed whole with water.
• Dosage should be individualized according to blood-glucose control, kidney function, hydration status, and other diabetes medicines.
• Patients using insulin or a sulfonylurea may require dose adjustment to reduce the risk of hypoglycemia.

For Children

• Safety and effectiveness in children and adolescents have not been established.
• Not recommended for pediatric use unless specifically prescribed by a specialist.
• No established pediatric weight-based dose is available.

Side Effects

• Common effects may include increased urination, thirst, dehydration, dizziness, urinary tract infection, genital fungal infection, nasopharyngitis, cough, or headache.
• Low blood sugar is more likely when used with insulin or sulfonylureas.
• Serious reactions may include ketoacidosis, severe dehydration, acute kidney injury, serious urinary or genital infection, pancreatitis, severe joint pain, or allergic reactions.
• Seek urgent care for facial or throat swelling, trouble breathing, severe abdominal pain, persistent vomiting, confusion, or markedly reduced urination.

Contraindications

• Do not use in patients with a known allergy to empagliflozin, linagliptin, or any formulation ingredient.
• Not indicated for type 1 diabetes or treatment of diabetic ketoacidosis.
• Use is unsuitable or may require avoidance in severe kidney impairment; kidney function should be assessed before and during treatment.
• Use cautiously in patients prone to dehydration, low blood pressure, recurrent urinary or genital infections, pancreatitis, or ketoacidosis.
• Temporarily stop and seek urgent medical advice if symptoms of ketoacidosis occur, such as nausea, vomiting, abdominal pain, unusual tiredness, or difficulty breathing.

Precautions & Warnings

• Insulin and sulfonylureas may increase the risk of hypoglycemia.
• Diuretics and medicines that lower blood pressure may increase the risk of dehydration or hypotension.
• Strong enzyme inducers such as rifampicin, carbamazepine, phenobarbital, and phenytoin may reduce linagliptin exposure and blood-glucose-lowering effect.
• Alcohol may increase dehydration and may contribute to ketoacidosis risk, particularly during illness or reduced food intake.
• Tell the prescriber about all medicines, including diuretics, corticosteroids, lithium, insulin, and other diabetes treatments.

Pregnancy

• Not generally recommended during pregnancy because of limited human safety data and potential fetal and neonatal kidney-development concerns.
• Patients who are pregnant, planning pregnancy, or who become pregnant should contact their healthcare professional promptly for treatment review.
• Breastfeeding is generally not recommended during treatment because it is not known whether the combination is safe for a nursing infant and empagliflozin may affect the developing kidney.